Xin Jing Bao·2025-10-29 04:21Core Insights - Fosun Pharma reported a revenue of 29.393 billion yuan for the first three quarters of 2025, a year-on-year decline of 4.91% [1] - The revenue from innovative drugs exceeded 6.7 billion yuan, showing a growth of 18.09% year-on-year [1] - The net profit attributable to shareholders reached 2.523 billion yuan, an increase of 25.5% year-on-year [1] Innovative Products - The company focuses on core treatment areas such as solid tumors, hematological tumors, and immune inflammation, enhancing its core technology platforms including antibodies, ADCs, cell therapy, and small molecules [1] - The innovative small molecule CDK4/6 inhibitor, Fovetisil Capsules, received approval for an additional indication in China for HR+/HER2- locally advanced or metastatic breast cancer [1] - The self-developed drug, Dushuan Antibody Injection (HLX14), was approved for sale in the US and EU, marking it as the first domestically produced Dushuan antibody approved overseas [1] R&D Investments - Fosun Pharma's R&D investment totaled 3.998 billion yuan in the first three quarters, a year-on-year increase of 2.12%, with R&D expenses amounting to 2.730 billion yuan [2] - In Q3, R&D expenses reached 1.013 billion yuan, up 28.81% year-on-year, primarily invested in innovative platforms including nuclear medicine and cell therapy [2] - The clinical trials for the innovative PD-1 inhibitor, Surulizumab, are progressing smoothly, with a Phase III trial for gastric cancer achieving its primary endpoint [2] New Business Initiatives - In September, Fosun Pharma established a nuclear medicine business platform, Xingrui Jingxuan, aiming to develop integrated diagnostic and therapeutic nuclear medicine products in the pan-tumor field [3]